Assignee
PREC BIOSCIENCES INC
US·48 granted patents·93 pending applications·411 citations·filing 2010–2025
Top patents by PatentIndex Score
141 records- 0199US10041053B2Rationally-designed single-chain meganucleases with non-palindromic recognition sequencesPREC BIOSCIENCES INC·Filed 2016·Granted Aug 7, 2018·43 cites·11 claims
- 0299US9434931B2Rationally-designed single-chain meganucleases with non-palindromic recognition sequencesPREC BIOSCIENCES INC·Filed 2015·Granted Sep 6, 2016·63 cites·4 claims
- 0399US9340777B2Rationally-designed single-chain meganucleases with non-palindromic recognition sequencesPREC BIOSCIENCES INC·Filed 2015·Granted May 17, 2016·49 cites·8 claims
- 0498US10851358B2Engineered meganucleases specific for recognition sequences in the hepatitis B virus genomePREC BIOSCIENCES INC·Filed 2020·Granted Dec 1, 2020·11 cites·13 claims
- 0598US9889161B2Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2017·Granted Feb 13, 2018·27 cites·4 claims
- 0698US9889160B2Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2017·Granted Feb 13, 2018·65 cites·9 claims
- 0797US10093900B2Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted Oct 9, 2018·15 cites·9 claims
- 0897US9993501B2Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted Jun 12, 2018·11 cites·13 claims
- 0997US9993502B1Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted Jun 12, 2018·16 cites·13 claims
- 1097US9969975B1Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted May 15, 2018·13 cites·9 claims
- 1197US9950010B1Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted Apr 24, 2018·14 cites·8 claims
- 1297US9950011B1Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted Apr 24, 2018·14 cites·8 claims
- 1395US10800833B2Co-stimulatory domains for use in genetically-modified cellsPREC BIOSCIENCES INC·Filed 2019·Granted Oct 13, 2020·7 cites·23 claims
- 1495US9683257B2Recognition sequences for I-CreI-derived meganucleases and uses thereofPREC BIOSCIENCES INC·Filed 2014·Granted Jun 20, 2017·10 cites·10 claims
- 1594US10287626B2Recognition sequences for I-CreI-derived meganucleases and uses thereofPREC BIOSCIENCES INC·Filed 2017·Granted May 14, 2019·5 cites·11 claims
- 1694US10093899B1Genetically-modified cells comprising a modified human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2018·Granted Oct 9, 2018·8 cites·9 claims
- 1793US11274285B2Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genomePREC BIOSCIENCES INC·Filed 2020·Granted Mar 15, 2022·2 cites·18 claims
- 1893US10799535B2Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2016·Granted Oct 13, 2020·5 cites·5 claims
- 1993US10662416B2Engineered meganucleases specific for recognition sequences in the hepatitis B virus genomePREC BIOSCIENCES INC·Filed 2017·Granted May 26, 2020·4 cites·9 claims
- 2093US10273524B2Recognition sequences for I-CreI-derived meganucleases and uses thereofPREC BIOSCIENCES INC·Filed 2017·Granted Apr 30, 2019·5 cites·11 claims
- 2191US11384335B2Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)PREC BIOSCIENCES INC·Filed 2021·Granted Jul 12, 2022·1 cites·3 claims
- 2291US11142750B2Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genomePREC BIOSCIENCES INC·Filed 2019·Granted Oct 12, 2021·3 cites·6 claims
- 2391US11053484B2Genetically-modified T cells comprising a modified intron in the T cell receptor alpha genePREC BIOSCIENCES INC·Filed 2018·Granted Jul 6, 2021·5 cites·10 claims
- 2491US10603363B2Treatment of retinitis pigmentosa using engineered meganucleasesPREC BIOSCIENCES INC·Filed 2016·Granted Mar 31, 2020·3 cites·10 claims
- 2591US2025121039A1Treatment of retinitis pigmentosa using engineered meganucleasesPREC BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 2690US11680254B2Engineered meganucleases specific for recognition sequences in the PCSK9 genePREC BIOSCIENCES INC·Filed 2018·Granted Jun 20, 2023·3 cites·8 claims
- 2790US11453861B2Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)PREC BIOSCIENCES INC·Filed 2022·Granted Sep 27, 2022·1 cites·8 claims
- 2890US11008548B2Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)PREC BIOSCIENCES INC·Filed 2020·Granted May 18, 2021·2 cites·3 claims
- 2989US12351839B2Rationally-designed single-chain meganucleases with non-palindromic recognition sequencesPREC BIOSCIENCES INC·Filed 2023·Granted Jul 8, 2025·0 cites·11 claims
- 3089US11186822B2Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)PREC BIOSCIENCES INC·Filed 2021·Granted Nov 30, 2021·1 cites·3 claims
- 3187US9822381B2Methods and products for producing engineered mammalian cell lines with amplified transgenesPREC BIOSCIENCES INC·Filed 2015·Granted Nov 21, 2017·2 cites·11 claims
- 3287US2024401110A1Recognition sequences for i-crei-derived meganucleases and uses thereofPREC BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 3387US2024002796A1Genetically-modified cells comprising a modified human t cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3487US2025082735A1Precise deletion of chromosomal sequences in vivo and treatment of nucleotide repeat expansion disorders using engineered nucleasesPREC BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 3587US2024238387A1Treatment of retinitis pigmentosa using engineered meganucleasesPREC BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3686US2024271111A1Engineered meganucleases specific for recognition sequences in the hepatitis b virus genomePREC BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 3786US2024156919A1Dystrophin gene exon deletion using engineered nucleasesPREC BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3885US11286291B2Co-stimulatory domains for use in genetically-modified cellsPREC BIOSCIENCES INC·Filed 2017·Granted Mar 29, 2022·2 cites·28 claims
- 3985US2025154481A1Engineered meganucleases specific for recognition sequences in the pcsk9 genePREC BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 4085US2024382526A1Nucleic acids encoding engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 4184US2024084252A1Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)PREC BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4284US2023088311A1Recognition sequences for i-crei-derived meganucleases and uses thereofPREC BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 4384US2024035011A1Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genomePREC BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4482US2024018215A1Co-stimulatory domains for use in genetically-modified cellsPREC BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4582US2022135945A1Genetically-modified cells comprising a modified human t cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 4682US2022145251A1Genetically-modified cells comprising a modified human t cell receptor alpha constant region genePREC BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 4781US12006522B2Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin genePREC BIOSCIENCES INC·Filed 2023·Granted Jun 11, 2024·0 cites·16 claims
- 4881US11993793B2Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin genePREC BIOSCIENCES INC·Filed 2023·Granted May 28, 2024·0 cites·16 claims
- 4981US11851680B2Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)PREC BIOSCIENCES INC·Filed 2022·Granted Dec 26, 2023·0 cites·3 claims
- 5081US2024101985A1Engineered meganucleases specific for recognition sequences in the pcsk9 genePREC BIOSCIENCES INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 141 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →